G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of G1 Therapeutics stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $19.96, for a total value of $14,970.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
G1 Therapeutics Inc (GTHX) traded down $0.18 on Monday, reaching $23.04. The company’s stock had a trading volume of 47,100 shares, compared to its average volume of 86,611. G1 Therapeutics Inc has a one year low of $12.04 and a one year high of $28.67.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.01. equities analysts predict that G1 Therapeutics Inc will post -2.72 EPS for the current year.
A number of analysts have commented on the company. BTIG Research assumed coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price on the stock. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.40.
TRADEMARK VIOLATION NOTICE: This piece was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/jennifer-k-moses-sells-750-shares-of-g1-therapeutics-inc-gthx-stock/1818603.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.